Isolair, Inc. has over 40 years of unsurpassed experience in the helicopter application industry. Our friendly and knowledgeable staff is here to provide around the clock support to each and every one of our customers, making Isolair the favorite amongst helicopter operators worldwide.
Iris Biotech GmbH
Iris Biotech is providing high quality products for the fields peptide synthesis, linkerology, drug delivery, and life sciences in flexible quantities from research scale to commercial production, for academia as well as industry. Besides our broad portfolio from standard to exotic, we have the know-how and facilities to manufacture your compound of choice based on a Custom Synthesis. All our services are rounded off by a strong and competent personnel customer support. We are in continuous exchange with scientists all around the world to gather ideas and be ahead regarding technologies and innovations true to our slogan Empowering Peptide Innovation. | Founded in 2001, Iris Biotech provides scientists in both industry and academia with innovative and rare compounds, while also being your reliable partner for a comprehensive supply of standard consumables. Guided by our dedication to deliver competent service as well as the highest quality to our customers, our company’s focus remains Peptide Chemistry, while we also have strong expertise in Drug Delivery, Life Sciences, and Linkerology. Due to the growing demand for tailor-made compounds and solutions, we further increased our Custom Synthesis capabilities in 2013. Our skilled scientists and technicians offer profound expertise in the custom manufacturing of both simple and complex molecules. | Empowering Peptide Innovation With this guiding theme in mind, Iris Biotech’s mission is to support researchers by supplying • innovative technologies, • rare compounds, • as well as a broad portfolio on standard consumables, available in flexible quantities from small scale to bulk quantities. Guided by our dedication to provide • competent service, • as well as novel substances and • latest technologies, Iris Biotech is your trusted partner for the world of peptides, while having strong expertise in associated disciplines. Thus, our portfolio comprises reagents and tools for the synthesis and modification of peptides, e.g., amino acids, resins and solvents but also for related technologies such as drug delivery, linkerology® and life sciences. Your project requires a compound not listed in our portfolio? Get in contact and inquire about our custom synthesis capabilities. | Empowering Peptide Innovation – this is our guiding principle. Iris Biotech stands for innovation and know-how in the field of pharmaceuticals and biotechnology. With this guiding theme in mind, Iris Biotech attends various conferences, symposia and exhibitions each year, which allows us to remain in direct contact with scientists from academia and industry alike, in order to exchange knowledge, and to gather new ideas to tackle your current challenges. Our mission as qualified supplier and competent consultant is to support our customers in their ongoing projects from research scale to commercial production.
iPark Institute Co., Ltd.
Shonan Health Innovation Park (Shonan iPark) is Japan’s firstpharmaceutical-initiated science park, established in April 2018 when Takeda Pharmaceutical Company Limited (Takeda) opened its then in-house research center to outside organizations. It aims to become a place where industry, government, and academia from a wide range of industries and sizes can come together to accelerate health innovation. Shonan iPark is currently home to about 190 companies and more than 2,500 people (as of February, 2025) from not only pharmaceutical companies but also next-generation medicine, cell agriculture, AI, government, and other fields, forming an ecosystem.
Invitris GmbH
Invitris co-develops highly complex multi-proteins using a scalable in vitro protein synthesis platform. Invitris provides both drug discovery & development, and can also provide GMP manufacturing without extensive process development. Invitris product portfolio includes synthetic bacteriophages, endolysins, tailocins, neoantigens, antibodies, ADCs, proteases, nucleases, enzymes, and many more. | We own a cell-free in vitro expression technology platform, PhactoryTM, to help co-develop & manufacture the next generation of proteins. We are capable of both prokaryotic and Mammalian cell-free expression. Our focus areas are microbial and Mammalian proteins, including bacteriophages, viruses, endolysins, tailocins, enzymes, antibodies, nanobodies, and more. We’re active in the fields of oncology, neurogenerative diseases, antibiotics, agriculture, technical industries, and more. | x
Inventage Lab Inc
.. | Inventage Lab(KOSDAQ: 389470) is a clinical-stage biopharmaceutical company specializing in drug delivery system, especially the development of long-acting injectables and lipid nanoparticles using a microfluidic manufacturing platform. IVL-DrugFluidic® platform enables the production of high-quality of microsphere based long-acting injectable formulations by eliminating initial drug over-release and ensuring the mass production of uniform microspheres. It has been successfully applied to veterinary medicine and clinical trials for androgenic alopecia, dementia, and addiction treatments. The platform also supports drug re-discovery and partnerships for novel drug formulations with partnering pharmaceutical companies. Harnessing our HANDYGENE™ system, this platform focuses on developing lipid nanoparticles (LNPs) for vaccines and gene therapies. Inventage Lab also offers services, including LNP formulation and non-clinical and clinical sample production, while diversifying its business through selling and subscribing to its LNP manufacturing equipment.
INTRAVACC
Intravacc is an established independent CDMO with years of experience in developing and optimizing vaccines for infectious diseases and therapeutic vaccines, which has transferred its technology worldwide for vaccines against polio, measles, diphtheria, Hib, and influenza. Around 30% of childhood disease vaccines are based on Intravacc’s technology and knowhow. Intravacc offers a wide range of expertise for independent vaccine development, from concept to Phase I/II clinical studies, for customers around the world. Intravacc continues to capitalize on the critical global trends in healthcare: the ever-growing need for prevention and intervention for infectious diseases and cancer. Our innovative vaccine platforms and vaccine contract development and manufacturing capabilities are well positioned to address the unmet needs in the vaccine and immune therapy market which is currently estimated at $37 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 6.6% to $55 billion by 2027. The company’s head office is located on the Utrecht Science Park location Bilthoven, The Netherlands, and has state-of-the-art laboratories and GMP production facilities. Intravacc B.V. is a limited liability company incorporated under Dutch law. Intravacc is a state holding company since 1 January 2021, under the Ministry of Health, Welfare and Sports (VWS). | . | Your specialized CDMO to accelerate the development of your viral, bacterial, therapeutic, and conjugate vaccines. From discovery to phase II clinical trial. Based in the Netherlands within the Utrecht Science Park in Bilthoven, Intravacc is a globally recognized pioneer and leader in translational vaccinology. With decades of experience, we stand as an independent Contract Development and Manufacturing Organization (CDMO) within the vaccine industry. Our purpose is to serve as the vital link between your discoveries and early-stage clinical trials of new vaccines. We understand that this journey from concept to GMP production is often riddled with challenges, and we specialize in mitigating risks and reducing costs. | Your specialized CDMO for viral, bacterial, therapeutic, and conjugate vaccines Based in the Netherlands and nestled within the Utrecht Science Park in Bilthoven, Intravacc is a globally recognized leader in translational vaccinology. With decades of experience, we stand as an independent Contract Development and Manufacturing Organization (CDMO) within the vaccine industry. Our purpose is to serve as the vital link between your discoveries and early-stage clinical trials. We understand that this journey from concept to GMP production is often riddled with challenges, and we specialize in mitigating risks and reducing costs. The entire team at Intravacc is committed to blazing new paths in vaccine development. We have an exceptional track record imagining and realizing technologies that enable tomorrow’s vaccines. That expertise in vaccine development is at the core of our CDMO services and candidate vaccines out-licensing.
Indian Immunologicals Ltd
Indian Immunologicals Limited (IIL) is a leading vaccine manufacturer. We are a fully integrated player, conceptualizing and executing the products journey from bench at the R&D lab to its sale at the clinic. Our journey of forty years of saving lives through developing, scaling up and executing huge scale manufacturing projects has honed our skills of projects management, efficient execution, excellence in regulatory compliance and at the same time offering agility, competitiveness, and trusted result-oriented approach. IIL has a strong portfolio of products, both in the human health segment and animal health segment. We have been spearheading the One Health initiative, globally. As a result of our presence in these two segments, we recognized both, the inter-dependence, and inter-linkages of the two segments and as a result have been spearheading the One Health initiative since a long time. IIL had its humble beginnings as a veterinary vaccine manufacturing company in the year 1982. Since then, it has scaled up to become one of the major vaccines manufacturer of the country and the region. We ventured into manufacturing human vaccines by 1998 on specific request by the Government of India. As a result, IIL became the second company in the world and first in India to launch purified vero cell rabies vaccine (PVRV) and markets it under the brand – Abhayrab. It is today by far the largest manufacturer of human rabies vaccine in the world. IIL today has a portfolio of eight commercial human vaccines and has a pipeline of nine new vaccine candidates. We have a huge pipeline of vaccine for Animal Health segment. We are one of the leading manufacturers of Pet Vaccines. IIL has four world class manufacturing facilities spread across India and New Zealand. IIL collaborates with several leading pharma/vaccines companies within India and outside for manufacturing and research collaborations. Our capabilities and experience in handling projects across varied platforms technologies, across varied scales (small to very high) enable us to offer both flexibility and confidence to our partners for a smooth execution. We solicit cooperation proposals to build synergistic relationships. | Indian Immunologicals Limited (IIL) is a leading vaccine manufacturer. We are a fully integrated player that conceptualizes and executes the products journey from bench at the R&D lab to its use at the clinic. Our journey of forty years of saving lives through developing, scaling up and executing huge scale manufacturing projects has honed our skills of projects management, efficient execution, excellence in regulatory compliance and at the same time offering agility, competitiveness, and trusted result-oriented approach. IIL has a strong portfolio of products, both in the human health segment and animal health segment. We have been spearheading the One Health initiative, globally. As a result of our presence in the two segments, we recognized both, the interdependence, and interlinkages of the two segments and as a result have been spearheading the One Health initiative for a long time. IIL has its humble beginnings as a veterinary vaccine manufacturing company in the year 1982. Since then, it has scaled up to become one of the major vaccines manufacturers of the region. After starting off an animal vaccine manufacturer, we started manufacturing human vaccines in 1998 on a specific request by the Government of India. As a result, IIL became the second company in the world and first in India to launch purified vero cell rabies vaccine (PVRV) and markets it under the brand – Abhayrab. It is today by far the largest manufacturer of human rabies vaccine in the world. IIL today has a portfolio of eight commercial human vaccines and has a pipeline of five new vaccine candidates. We are currently serving and touching lives in more than fifty (60) countries by exporting both our animal health and human health products. We have four world class manufacturing units spear across India and New Zealand. IIL, through its state-of-the-art facilities, collaborates with several leading pharma/vaccines companies within India and outside.
INDIA PAVILION
Association of Biotechnology Led Enterprises – ABLE is a not-for-profit pan-India forum that represents the Indian Biotechnology Sector. It was launched in April 2003, after industry leaders felt a need to form an exclusive forum to represent the Indian Biotechnology Sector. ABLE has over 400 members from all across India representing all verticals of the sector like Agribiotech, Bio-pharma, Industrial biotech, Bioinformatics, Investment banks and Venture Capital firms, leading Research and Academic Institutes and Law Firms and Equipment Suppliers. The primary focus of ABLE is to accelerate the pace of growth of the Biotechnology sector in India, through partnering with the Government in their biotechnology initiatives to deliver optimal policies and create a positive regulatory environment, encouraging entrepreneurship and investment in the sector, providing a platform for domestic and overseas companies to explore collaboration and partnerships, forging stronger links between academia and industry and showcasing the strengths of the Indian biotech sector. | Association of Biotechnology Led Enterprises – ABLE is a not-for-profit pan-India forum that represents the Indian Biotechnology Sector. It was launched in April 2003, after industry leaders felt a need to form an exclusive forum to represent the Indian Biotechnology Sector. ABLE has over 400 members from all across India representing all verticals of the sector like Agribiotech, Bio-pharma, Industrial biotech, Bioinformatics, Investment banks and Venture Capital firms, leading Research and Academic Institutes and Law Firms and Equipment Suppliers. The primary focus of ABLE is to accelerate the pace of growth of the Biotechnology sector in India, through partnering with the Government in their biotechnology initiatives to deliver optimal policies and create a positive regulatory environment, encouraging entrepreneurship and investment in the sector, providing a platform for domestic and overseas companies to explore collaboration and partnerships, forging stronger links between academia and industry and showcasing the strengths of the Indian biotech sector. ABLE showcases India’s biotech sector through events like BioEconomy Conclave, Voice for BT public speaking contest, brings out India BioEconomy Report, BioEconomy Reports for states like Karnataka and sets up the India Pavilion at the BIO International event in the USA annually. ABLE Council of Presidents, that comprises of all past presidents of the organization, provides valuable inputs for the growth of the Biotech business ecosystem, leveraging their multi-sectoral expertise. ABLE thus catalyses a symbiotic interface between the industry, the government, academic and research institutes and domestic and international investors. | Association of Biotechnology Led Enterprises – ABLE is a not-for-profit pan-India forum that represents the Indian Biotechnology Sector. It was launched in April 2003, after industry leaders felt a need to form an exclusive forum to represent the Indian Biotechnology Sector. ABLE has over 400 members from all across India representing all verticals of the sector like Agribiotech, Bio-pharma, Industrial biotech, Bioinformatics, Investment banks and Venture Capital firms, leading Research and Academic Institutes and Law Firms and Equipment Suppliers. The primary focus of ABLE is to accelerate the pace of growth of the Biotechnology sector in India, through partnering with the Government in their biotechnology initiatives to deliver optimal policies and create a positive regulatory environment, encouraging entrepreneurship and investment in the sector, providing a platform for domestic and overseas companies to explore collaboration and partnerships, forging stronger links between academia and industry and showcasing the strengths of the Indian biotech sector. ABLE showcases India’s biotech sector through events like BioEconomy Conclave, Voice for BT public speaking contest, brings out India BioEconomy Report, BioEconomy Reports for states like Karnataka and sets up the India Pavilion at the BIO International event in the USA annually. | Stop by the booth to learn more! | Government of India/Ministry of Ports, Shipping and Waterways has established the Cruise Bharat Mission Secretariat under the aegis of the Indian Ports Association. Cruise Bharat Mission focuses on three cruise segments- Ocean & Harbour Cruise, River & Inland Cruise and Island Cruise.
iBody Inc.
iBody has an unique monoclonal antibody generating technology called “Ecobody” that integrates single-cell technology and in vitro antibody expression technology. The “Ecobody” enables us to obtain monoclonal antibodies rapidly and efficiently from rabbits and humans, thereby producing antibodies with excellent properties necessary for therapeutics, diagnostics and reagents. | iBody has a patent protected monoclonal antibody discovery platform technology. It enabled us the exhaustive and world fastest (2 days) monoclonal antibody discovery. We have commercial success in monoclonal antibody discovery for pharmaceutical and diagnostic drug companies in Japan. These monoclonal antibodies have been applied to drug discovery, diagnostic drug development, and research tools. Platform technology: Extremely effective antibody discovery technology, which integrates single cell and cell free antibody technologies. Advantage: iBody technology enables discovering highly functional monoclonal antibodies that are difficult to obtain conventional technologies. Business model: – Contract research (Service) – Collaborative research | iBody Inc. is a Japan-based biotechnology company with a proprietary antibody discovery platform that integrates single-cell technology with cell-free antibody expression. This unique combination enables extremely comprehensive and rapid antibody screening, allowing the discovery of antibodies that are difficult or impossible to generate using conventional methods. Our platform enables the discovery of high-performance antibodies from diverse sources, including rabbits, alpaca-derived VHH, and human samples. It is particularly powerful for challenging targets such as small molecules, post-translational modifications, single amino acid variants, and GPCRs. Building on this platform, we collaborate with pharmaceutical and diagnostic companies, and academics on antibody discovery programs. To date, we have advanced more than 100 programs with leading partners across pharma, diagnostics, and academia, consistently delivering high-value antibodies for difficult targets.
Hong Kong Baptist University: Institute for Innovation, Translation and Policy Research
Hong Kong Baptist College was founded by the Baptist Convention of Hong Kong in 1956. In 1983, it became a fully funded public tertiary institution, and the College gained university status just over a decade later. It was renamed Hong Kong Baptist University (HKBU) in 1994. The Institute for Innovation, Translation and Policy Research (ITPR) within HKBU serves to drive innovations, research and development, technology translation, and applications to enable HKBU to respond to emerging challenges and opportunities globally, nationally, as well as those under the aegis of the Hong Kong SAR Government’s top policy priority on innovation and technology development. ITPR strives to bridge the gap in technology readiness between academic innovation and industry applications. ITPR also helps to advance HKBU’s innovation capacity and enhance up- to mid-stream research and technology development capabilities through establishing collaborative platforms, engaging stakeholders, facilitating high-impact innovation and multidisciplinary R&D.